Glaukos Corporation

Glaukos Corporation is the company identified by ticker GKOS on this research page. Use the overview to review the business, financial results, valuation and related news.

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Check the GKOS quote and chart on the overview and Chart tabs. Confirm the quote time, currency and trading session before comparing prices; a research update time is not a quote timestamp.

The Forecast tab shows available analyst price targets for GKOS. Analyst targets are separate from BTI scores and valuation estimates. Missing targets are unavailable, and forecasts do not guarantee returns.

Review Glaukos Corporation's investor-relations announcements for declared dividends, ex-dividend dates and payment dates. A missing or zero yield in a data feed alone does not establish the company's dividend policy.

Check the Earnings tab for available dates and reported results, then confirm the next announcement with Glaukos Corporation's investor-relations calendar. Estimated dates may change.

Compare GKOS's Valuation and Financials tabs, including cash flow, growth assumptions and valuation multiples. BTI estimates depend on their inputs and are different from analyst price targets.

Review Glaukos Corporation's latest company filings for business-specific risks, alongside debt, profitability, competition and valuation. A BTI score summarizes research and is not a personalized investment recommendation.